{"schema_version":"secwatch.filing_event.v1","accession":"0001326110-26-000014","form_type":"8-K","ticker":"IBRX","cik":"0001326110","company_name":"ImmunityBio, Inc.","filed_at":"2026-01-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.807090+00:00","generated_at":"2026-05-16T07:51:01.237254+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ImmunityBio amends $505M convertible note to allow partial conversion at any time","bullets":["Convertible note amendment allows holder Nant Capital to convert any portion of $505M principal into common stock at any time before maturity.","Previously, partial conversion was not permitted under the December 2024 note; no other terms changed.","Holder Nant Capital is an affiliate of Executive Chairman Dr. Patrick Soon-Shiong, making this a related-party transaction."],"urls":{"canonical":"https://secwatch.observer/filing/0001326110-26-000014","json":"https://secwatch.observer/filing/0001326110-26-000014.json","markdown":"https://secwatch.observer/filing/0001326110-26-000014.md","text":"https://secwatch.observer/filing/0001326110-26-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000014/0001326110-26-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000014/ibrx-20260123.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T07:51:01.237254+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5c56a3dc7d522cfafc9364c614119b38238cfa13","claim":"ImmunityBio, Inc. amended Convertible Note Amendment with Nant Capital, LLC (effective 2026-01-23).","evidence_excerpt":"On January 23, 2026, ImmunityBio, Inc. (the “Company”) entered into a letter amendment (the “Convertible Note Amendment”) to that certain convertible Second Amended and Restated Promissory Note, dated December 10, 2024, in an outstanding principal amount of $505.0 million (the “Convertible Promissory Note”), by and among the Company and Nant Capital, LLC (the “Holder”), an entity affiliated with Dr. Patrick Soon-Shiong, the Company’s Executive Chairman and Global Chief Scientific and Medical Officer.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000014/0001326110-26-000014-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"Nant Capital, LLC"},{"label":"Effective","value":"2026-01-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}